Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 11/20 | 0.48 |
| ▸ | CSNK1E | P49674 | 11/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004854 | 0.91 | MAPK14 (0.46) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL6004040 | 0.89 | CSNK1E (0.50) | CSNK1DCSNK1EMAPK14 | |
| SCHEMBL6004454 | 0.88 | CSNK1E (0.47) | CSNK1DCSNK1EMAPK14IRAK4MAPK13 | |
| Isopropylamine SCHEMBL4791212 | 0.88 | MAPK14 (0.47) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL4915605 | 0.88 | MAPK14 (0.47) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL6002781 | 0.88 | CSNK1E (0.47) | CSNK1DCSNK1EMAPK14IRAK4MAPK13 | |
| SCHEMBL4791217 | 0.86 | MAPK14 (0.46) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 | |
| SCHEMBL4719198 | 0.86 | MAPK14 (0.57) | CSNK1DMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6003859 | 0.85 | MAPK14 (0.54) | CSNK1DCSNK1EMAPK14PIN1 | |
| SCHEMBL4789586 | 0.81 | MAPK14 (0.51) | CSNK1DCSNK1EMAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | CSNK1D 1696/4885CSNK1E 1579/4885MAPK14 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.